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Review
Pharmacologic Therapy That Simulates
Conditioning for Cardiac Ischemic/
Reperfusion Injury
Vivek Sivaraman, MBBS, MRCP, MD, FRCA1, and
Derek M. Yellon, PhD, DSc, FRCP, FESC, FACC1
Abstract
Cardiovascular disease remains a leading cause of deaths due to noncommunicable diseases, of which ischemic heart disease
forms a large percentage. The main therapeutic strategy to treat ischemic heart disease is reperfusion that could either be medical
or surgical. However, reperfusion following ischemia is known to increase the infarct size further. Newer strategies such as
ischemic preconditioning (IPC), ischemic postconditioning, and remote IPC have been shown to condition the myocardium to
ischemia–reperfusion injury and thus reduce the final infarct size. Research over the past 3 decades has deepened our under-
standing of cellular and subcellular pathways that mediate ischemia–reperfusion injury. This in turn has resulted in the devel-
opment of several pharmacological agents that act as conditioning agents, which reduce the final myocardial infarct size following
ischemia–reperfusion. This review discusses many of these agents, their mechanisms of action, and the animal and clinical evidence
behind them.
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Ischemic heart disease is a major cause of morbidity and mor-
tality in both the developing and the developed world. Despite
several therapeutic advances, both medical and surgical, which
have occurred in the past few decades, cardiovascular disease
remains the leading cause of deaths due to noncommunicable
diseases. The Global Health Observatory data from the World
Health Organization makes for uncomfortable reading. For
instance, 1 in 10 adults in the world are diabetic, 25% of the
adults in the world are overweight, while 20% are clinically
obese. Furthermore, 40% of the adults have raised blood
pressure, 39% have raised cholesterol, and 22% of the world’s
population still smoke. The burden of ischemic heart disease is
set to rise, and therapeutic strategies are needed to tackle this
burden on multiple fronts.1
One target is to reduce ischemic–reperfusion injury that
occurs when ischemic myocardium is reperfused with oxygen
and substrate-rich blood paradoxically worsening the infarct
size.2 During primary percutaneous coronary intervention
(PCI), this occurs at the point of balloon deflation after infla-
tion to clear an occluded coronary vessel, and in cardiac sur-
gery, it occurs when the aortic cross-clamp is removed.
Animal and human studies have shown that it is possible to
reduce myocardial ischemic–reperfusion injury by ‘‘condition-
ing’’ the heart. Conditioning is thus a broad term used to
describe a phenomenon that reduces infarct size at the point
of reperfusion. Ischemic preconditioning (IPC) was originally
described in 1986, when multiple cycles of ischemia followed
by reperfusion of the myocardium prior to the onset of pro-
longed lethal ischemia, resulted in a smaller infarct size in
dogs.3 Subsequently described in rats and dogs were similar
cycles applied at the point of reperfusion of the myocardium,
referred to as ischemic postconditioning.4,5 It was further dis-
covered that these ischemic cycles when applied to a remote
region or an organ had a similar protective effect on heart mus-
cle that had been subjected to prolonged lethal ischemia,
a strategy coined remote IPC (RIPC).6 Over the last few decades,
research into the mechanisms of conditioning has revealed
multiple receptors, pathways, and end effectors, all of which
can be pharmacologically stimulated (Figure 1).
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Reperfusion Injury
Animal studies have revealed that reperfusion alone may con-
tribute to a significant percentage of the final infarct size.
Exactly, how much injury is caused by reperfusion of the
human myocardium, however, has been difficult to quantify,
although it is assumed to be in the region of up to 50%.7 During
ischemia, lack of oxygen supply to the myocardium results in
depleted adenosine triphosphate (ATP) levels. The ensuing
anaerobic glycolysis results in the production of lactic acid and
a decrease in both intracellular and extracellular pH. In an
effort to correct this anomaly, the Naþ/Hþ exchanger draws
Naþ into the cell while pushing out Hþ. The increase in intra-
cellular Naþ, which is normally an extracellular cation, causes
the Naþ/Ca2þ exchanger to function in reverse mode carrying
Naþ out of the cell and Ca2þ into the cell. Furthermore, the
continued anaerobic metabolism, with a lack of blood flow,
results in the accumulation of waste metabolites. This increases
the osmolality of the internal cell environment resulting in flow
of water into the cells along the gradient causing cell swelling.
The net result is an intracellular environment that is acidic, rich
in cytosolic calcium, and swollen from inflow of the solvent.8
Reperfusion has injurious effects, as it results in a sudden oxi-
dative load and rapid pH correction in a damaged cell that has
impaired calcium handling. The Ca2þ/Naþ exchanger contin-
ues to work in the reverse mode causing a further accumulation
of calcium. The calcium-rich oxidative environment created
within the myocyte results in the opening of a mitochondrial
permeability transition pore (MPTP) on the inner mitochon-
drial membrane, which causes the release of proapoptotic fac-
tors, triggering cell death. Furthermore, the presence of oxygen
radicals attracts inflammatory cells such as neutrophils result-
ing in the release of cytotoxic agents that worsen myocardial
damage.7,9,10
Cellular Pathways Underlying
Ischemic Conditioning
Although a detailed review of the mechanisms of IPC and post-
conditioning is beyond the scope of this article, one among sev-
eral authoritative reviews on the subject has been suggested in
the reference.11 Several thousand research articles have been
published which have attempted to explain the mechanism of
ischemic conditioning over the last 3 decades. In brief, IPC
results in the release of substances such as adenosine, bradyki-
nin, endogenous opioids, and other growth factors. These sub-
stances bind to the cell surface receptors, which in turn activate
cardioprotective pathways. Enzymes that have been shown to
be involved in this pathway include phosphotidylinositol-3-
phosphate kinase, protein kinase B (PKB or Akt), endothelial
nitric oxide synthase (eNOS), extracellular signal-regulated
protein kinases 1 and 2 (ERK1/2), protein kinase C (PKC), and
Janus kinase and signal transducer and activator of transcrip-
tion (JAK-STAT), a set of kinases that has been termed by
Yellon as the reperfusion injury salvage kinase (RISK) path-
way.11,12 Other pathways suggested to contribute to the condi-
tioning phenomenon include the Survivor Activating Factor
Enhancement pathway and possibly the 50-adenosine
monophosphate-activated kinase pathway.13,14 Once the cell
has been preconditioned, these pathways are activated at reper-
fusion, which results in a cascade of reactions that ultimately
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Figure 1. Receptors, Pathways and End-Effectors involved in the Conditioning Pathway.
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prevent the opening of the MPTP. The mitochondria in the cell
thus continue to function without the release of proapoptotic
factors, and this prevents cell death (Figure 1). However, the
exact mechanisms remain unclear, especially how it is that the
heart ‘‘remembers’’ that it is preconditioned. Similar mechan-
isms have been described with regard to ischemic postcondi-
tioning, mainly implicating the RISK pathway and the
MPTP. Pharmacological therapy can thus simulate condition-
ing by targeting the cell at one of these points—at the level
of the receptor, the signal transduction pathways, or the MPTP.
Pharmacological Agents That Activate
Cardiomyocyte Receptors
Adenosine
In 1991, Liu et al described how 2 nonselective adenosine
antagonists could block the protection afforded by IPC in rabbit
hearts, first implicating a potential therapeutic role for adeno-
sine. Furthermore, the intracoronary administration of an ade-
nosine A1 receptor (A1R) agonist caused the same infarct
size reduction as seen in preconditioned hearts.15 The activa-
tion of this was subsequently linked to PKC and other enzymes
of the RISK pathway.16,17
Taking the animal evidence forward, the Acute Myocardial
Infarction STudy of Adenosine (AMISTAD) study proceeded
to randomize 236 patients, who had been treated with thrombo-
lysis, to receive an infusion of adenosine or placebo. Infarct
size was assessed using single-photon emission computed
tomography (SPECT) that showed a 33% relative reduction
in infarct size in the group that received adenosine. Further
analysis suggested that the group with anterior myocardial
infarction (MI) benefitted the most from adenosine with a 67%
relative reduction in the infarct size.18 The AMISTAD-II was
published in 2005, which examined the effects of adenosine in
2118 patients who were admitted with an anterior ST-segment
elevation MI (STEMI). They were randomized to receive an
intravenous 3-hour infusion of either adenosine 50 or 70 mg/
kg/min or placebo prior to reperfusion. Infarct sizes, as deter-
mined by SPECT, were reduced with 70 mg/kg/min of adeno-
sine, which correlated with the reduced clinical events.
However, it did not reduce the primary end point of survival
without rehospitalization with congestive heart failure
(CHF).19 A subsequent post hoc analysis revealed that patients
who received adenosine within 3.17 hours had improved
survival.20
There are several subtypes of adenosine receptors, which
may reduce the side effects of adenosine and result in better
outcomes. Adenosine acts via 4 known adenosine receptors—
A1, A2a, A2b, and A3. Animal studies have suggested that the
A2b receptor appears to play a crucial role in cardioprotec-
tion.21,22 AMP579 is an adenosine receptor agonist that acts
on A1 and A2a receptors. The AMP579 Delivery for Myocar-
dial Infarction Reduction (ADMIRE) investigators adminis-
tered AMP579 prior to PCI in patients having an STEMI.
They used 3 different doses but found no difference in infarct
sizes.23 There are several potential reasons for a negative result
in this trial. First, AMP579 was administered to patients at a
median time period of 0.37 hours prior to reperfusion. Further-
more, only an infusion was given with no bolus dose. It is likely
that the concentration of AMP579 was not sufficient at the
point of reperfusion and for several hours after. Second, the
authors state that the steady state concentration of the drug was
achieved only in 4 to 6 hours. It is thus likely that the blood
concentration of AMP579 varied greatly among patients.
Moreover, it has been recently suggested that it is the A2b activ-
ity that is crucial to AMP579’s cardioprotective effect.24 A2b is
a low-affinity receptor that requires a dose of agonist that is
high enough to bind to the receptor to result in activity. The ani-
mal evidence for infarct size reduction with AMP579 is robust,
with timing, dosage, and duration of administration being cru-
cial determinants.25,26
Bradykinin
Wall et al were able to prove that bradykinin reduced infarct
size just as much as IPC using intra-atrial infusions of bradyki-
nin in an in vivo rabbit model. A bradykinin receptor antago-
nist, HOE 140, blocked the protective effect of IPC. It was
thus possible that bradykinin was also a trigger released by
an IPC stimulus.27 Subsequent experiments in other animal
models have shown a crucial role for bradykinin via the B2
receptor.28 Angiotensin-converting enzyme (ACE) inhibition
results in the accumulation of bradykinin. Although some stud-
ies using ACE inhibitors alone with the aim of conditioning the
heart have been positive,29-31 others have suggested that ACE
inhibitors provide a subthreshold level of conditioning, and
a further stimulus is needed to enhance its effects.32,33
The data in humans regarding bradykinin are more contro-
versial. A total of 41 patients undergoing isolated coronary
artery bypass grafting (CABG) were randomized to receive a
bradykinin infusion or nothing prior to cardiopulmonary
bypass. Patients who received bradykinin had lower creatinine
kinase (CK)-MB release, but the troponin I levels were the
same in both the groups.34 Conversely, Perdersen et al con-
ducted a randomized, double-blind crossover trial in healthy
male volunteers, using a forearm endothelium-mediated vaso-
motor dysfunction model. Their findings did not support any
role for bradykinin in humans.35 With regard to ACE inhibi-
tors, there are several large clinical trials showing good out-
comes with the administration of these drugs after MI.36 In
the context of acutely conditioning the heart during reperfu-
sion, enalaprilat has been administered directly into the coron-
ary artery during reperfusion in several small clinical trials with
improvement in ST-segment elevation, ventricular repolariza-
tion, arrhythmias, and inflammation.37-39
Opioids
In 1995, Schultz et al provided evidence for the involvement of
opioid receptors in male Wistar rat hearts using naloxone, a
nonselective opioid receptor antagonist, to block the protective
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effects of IPC.40 Clinical studies examining the effect of
opioids in humans, however, have been slow to emerge. Con-
founding this may be the fact that many patients having CABG
surgery or admitted with an evolving STEMI are given opioids.
Nonetheless, in a study of 40 patients by Wong et al, remifen-
tanil infusions given to a group of 20 patients having CABG
surgery was associated with a reduction in CK-MB release at
24 hours and a reduced troponin I release at 12 hours.41,42
Although associated with a reduced time to tracheal extubation,
a lesser need for defibrillation postreperfusion and a lower
incidence of arrhythmias postoperatively, the study was not
powered to look at mortality data. Additionally, the intensive
care unit (ICU) and hospital stays were no different in either
group. It is thought that preconditioning is triggered via the k
and d opioid receptors in animal models,43 but remifentanil is
an opioid that acts on m receptors, demonstrating the heteroge-
neity that exists between various species. Overall, the effects of
opioids are under investigated in humans and need further
probing.
Glucagon-Like Peptide 1 (GLP-1)
Glucagon-like peptide 1 (GLP-1), an incretin hormone, is
secreted by the duodenum and the jejunum in response to
intestinal glucose load, even before blood glucose levels have
risen. GLP-1 has been shown to reduce infarct size when admi-
nistered to animal hearts by our group and by others.44,45 It is
likely that GLP-1 acts via a surface receptor present on
the cardiomyocyte and activates downstream signaling kinases
of the RISK pathway.44 It is broken down within a few minutes
by the enzyme dipeptidyl peptidase 4 (DPP-4).46 Thus, DPP-4
inhibitors such as sitagliptin, vildagliptin, and saxagliptin could
prolong the action of GLP-1 by preventing their breakdown.
There is certainly animal evidence for the infarct reducing
effects of vildagliptin and sitagliptin.47-49 However, the DPP-
4 inhibitors are yet to be tested in patients with regard to their
conditioning effect.
Another group of drugs are the GLP-1 receptor agonists.
There are currently 2 agonists that are licensed for use in the
treatment of type 2 diabetes, exenatide and liraglutide. Both
these agents have been shown to be cardioprotective in animal
models that have been discussed in detail in a review.50
A recent clinical trial examined the effect of exenatide in 172
patients presenting with a STEMI.51 Exenatide was started as
an infusion 15 minutes prior to primary PCI, continued for 6
hours afterward, and was compared to placebo. In all, 90% of
the patients were nondiabetic. Cardiac magnetic resonance
imaging (MRI) 90 days later showed improved myocardial
salvage in patients who received exenatide.52
Atrial Natriuretic Peptide
Atrial natriuretic peptide (ANP) is a 28 amino acid peptide pro-
duced by atrial cardiomyocytes in response to distention and
ischemia.53 It acts on a guanylyl cyclase-coupled receptor that
is present in various organs in the body.54 Downstream, it is
likely that ANP acts on several targets including a cyclic gua-
nosine monophosphate (cGMP)-coupled protein kinase G
(PKG), components of the RISK pathway, and even MPTP,
exerting a protective action on the myocardium and reducing
the infarct size.55,56
The largest human trial to date examining the effect of ANP
was conducted by the Japan-Working groups of acute myocar-
dial Infarction for the reduction of Necrotic Damage (J-
WIND). After PCI at a dose of 0.025 mg/kg/min intravenously
for 3 days, 569 patients were randomized to receive either ANP
or placebo. Of the 535 patients that had a complete data set, 255
patients received ANP and had a smaller infarct size as deter-
mined by CK area under the curve (CK-AUC) over 72 hours.
Furthermore, these patients had a significantly better ejection
fraction at 6 months compared to the control group. Addition-
ally, rehospitalization due to heart failure and death due to
cardiac causes were lower in the group that received ANP.57
Other studies using ANP have shown benefit,58,59 but larger
randomized trials are yet to be conducted.
Erythropoeitin
Erythropoeitin (EPO) is a glycoprotein hormone produced by
various organs in the body including kidney, liver, vascular
smooth muscle, and cardiac muscle. It exerts its effects through
a transmembrane erythropoietin receptor (EPOR) that is a type
of cytokine receptor.60 The formation of both EPO and EPOR
is brought about by hypoxia, likely to be through the production
of the hypoxia-inducible factor 1.61 EPO has been linked to
various enzymes involved in the cardioprotective pathway
including PI3-K, Akt, JAK-STAT, and glycogen synthase
kinase 3b (GSK-3b), in the prevention of apoptosis62,63 and
ultimately to the formation of the MPTP,64 thus reducing
infarct size.
Clinical studies using EPO around the time of reperfusion
have been conflicting. In a double-blinded, randomized, pla-
cebo-controlled trial conducted by our group, 51 patients who
were admitted to a tertiary cardiac center with STEMI received
an intravenous bolus of 50 000 IU of EPO prior to PCI and a
further bolus 24 hours later. There was no improvement in any
outcomes that were measured. In fact, there was an increased
incidence of microvascular obstruction (MVO), left ventricular
(LV) dilation, and LV mass in the group that received EPO.65
Similarly, in the REVEAL study, investigators who rando-
mized 222 patients to receive 60 000 IU of EPO within 4 hours
of reperfusion found no reduction in infarct size and a higher
rate of adverse cardiovascular outcomes (death, MI, stroke, and
stent thrombosis). Furthermore, a subgroup analysis revealed
larger infarct sizes in older patients.66 The REVIVAL-3 trial67
and the HEBE-III trials were also negative.68 Similar studies in
the cardiac surgical setting have been disappointing.69,70 On
the other hand, in a smaller trial involving 30 patients that
received 33 000 IU of EPO prior to PCI intravenously and fur-
ther boluses 24 and 48 hours later, there was a reduction in the
primary outcome measure of CK-MB AUC and thus myocar-
dial injury. Measures of inflammation were also markedly
86 Journal of Cardiovascular Pharmacology and Therapeutics 19(1)
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reduced, and gene expression shifted toward the antiapoptotic
spectrum.71 Additionally, a different regime of 1000 IU/kg of
EPO given intravenously immediately following reperfusion
in a randomized trial by Prunier et al showed a reduced inci-
dence of MVO in the EPO group along with a short-term
improvement in LV volume and function.72 Similar intrave-
nous regimes in 2 other trials showed improvement in LV func-
tion in favor of EPO.73,74 Thus, the infarct-reducing
capabilities of EPOmay be demonstrated, if the dosage, timing,
and route of administration are optimized. Given the volume of
evidence in laboratory data combined with the positive trials,
interest in EPO has not waned. Although the results of the
EPOMINONDAS trial is eagerly anticipated,75 the EPO-
AMI-II study has started recruiting patients to receive intrave-
nous EPO within 6 hours of reperfusion,76 and the ICEBERG
trial aims to administer intracoronary EPO to patients before
reperfusion.77
Insulin
Insulin is a peptide hormone secreted by the b cells of the pan-
creas. It binds to a tyrosine kinase transmembrane receptor to
exert its effects.78 Similar to EPO, the evidence for insulin
administration resulting in activation of cardioprotective path-
ways has been repeatedly provided by our group and others79,80
and has also been linked to closure of the MPTP.81 However,
insulin administration per se would result in hypoglycemia and
hypokalemia, so it was examined in animal models as a glu-
cose–insulin–potassium (GIK) infusion. In an in vivo rabbit
model, GIK administration resulted in reduced infarct size and
decreased indices of apoptosis.82 Similar results were obtained
in vivo in dogs and pigs.83,84
Translation into the clinical setting of reperfusion injury has
proved disappointing. The largest trial involving GIK to date,
Clinical Trial of Reviparin and Metabolic Modulation in Acute
Myocardial Infarction Treatment Evaluation-Estudios Cardio-
logicas Latin America (CREATE-ECLA), did not show any
improvement in morbidity or mortality.85 This trial recruited
20 201 patients in 470 centers worldwide. The protocol
described the initiation of GIK administration prior to PCI or
immediately after thrombolysis in patients presenting with
AMI. However, 68% of the patients received the GIK infusion
after thrombolysis or PCI. A large majority of recruited patients
were thrombolyzed, and even patients who received GIK prior
to thrombolysis or PCI did not have any benefit in terms of
morbidity or mortality. In fact, the mortality was slightly higher
in the group that received GIK prior to reperfusion (12.2% vs
8.2%). In Organization for the Assessment of Strategies for
Ischemic Syndromes 6 (OASIS-6), 2748 patients were
recruited into a similar trial with a similar protocol.86 Patients
received GIK soon after presentation prior to reperfusion
therapy, and yet the study showed no outcome benefit.
OASIS-6 seemed to suggest that glucose and potassium thrown
into the milieu may have been confounding factors as both
independently predicted death and heart failure at 3 days. On
a different note, animal studies using low-dose insulin that does
not cause hypoglycemia appeared to have the same benefits as
GIK.83 Moreover, in a recent randomized controlled trial,
Immediate Myocardial Metabolic Enhancement During Initial
Assessment and Treatment in Emergency Care (IMMEDI-
ATE), where 871 patients with a high probability of an acute
coronary syndrome (ACS) were randomized to receive GIK
or placebo in the ambulance prior to arrival at the hospital, GIK
was associated with lower rate of cardiac arrest and inhospital
mortality. The 30-day survival was the same in both the
groups.87 In the cardiac surgical setting, interest for GIK still
exists with several small trials that are positive. In a meta-
analysis of 33 trials and 2113 patients, GIK infusions were
associated with a lower incidence of perioperative MI, lower
requirement for inotropic support, better cardiac index, and
reduced ICU stay. Duration of hospital stay, postoperative
atrial fibrillation, and all-cause mortality were, however, the
same between the placebo and the GIK groups.88
Pharmacological Agents Acting on
Intracellular Signal Transduction Pathways
Volatile Anesthetics
In 1983, Davis et al randomized 28 dogs to receive Halothane
(n¼ 18) for 12 hours, starting 1 hour after left anterior descend-
ing coronary artery ligation, or to awaken on room air without
further intervention (n ¼ 10). After 24 hours, the heart was
excised, and triphenyltetrazolium chloride staining was done
for infarct size measurement. Dogs that received halothane had
a significantly smaller infarct size.89 Although this preceded
Murry’s seminal article in 1986,3 the first evidence of volatile
anesthetics providing a conditioning effect was first described
by Cope et al, where rabbits anesthetized with halothane,
enflurane, and isoflurane showed reduced myocardial infarct
sizes as compared to rabbits anesthetized with pentobarbital,
propofol, or ketamine-xylazine.90 Subsequent evidence in ani-
mal models proved that other volatile anesthetics, such as sevo-
flurane and desflurane, provide a preconditioning effect.91
Volatile anesthetics have since been shown to work via the
same pathways that are involved in IPC, including the adeno-
sine receptor, PI3-K/Akt, MEK1/2, ERK1/2, PKC, large-
conductance, calcium-activated potassium (BKCa) channels,
and MPTP.92
The first human studies were conducted with enflurane and
isoflurane in the setting of on-pump cardiac surgery that
showed better LV contractility and reduced troponin I and
CK-MB AUC, respectively, with the use of these agents.93,94
These studies applied the anesthetic agents in a preconditioning
protocol prior to reperfusion. Subsequent studies seemed to
suggest that it was unnecessary to use the volatile anesthetics
in a preconditioning protocol, but if used as the primary anes-
thetic agent throughout the course of the surgery, resulted in
reduced perioperative myocardial injury and reduced stay in
ICU and in hospital, with better myocardial contractility over-
all.95,96 Studies have also looked at long-term outcomes. In
a placebo-controlled trial by Garcia et al, 72 patients subjected
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to a preconditioning protocol with sevoflurane had a lower
incidence of late cardiac events.97 There have been negative
studies as well. In a study by De Hert et al, 414 patients were
randomized to receive sevoflurane, desflurane, or propofol.
There was no difference in troponin I release or 1-year mortal-
ity between any of the groups. However, the length of hospital
stay was reduced in the group that received sevoflurane and
desflurane.98 Larger trials are needed, however, to examine the
cardioprotective action of anesthetic agents.
Phosphodiesterase (PDE)-5 Inhibitors
PDE-5 is an intracellular enzyme that degrades cGMP within
the cell. Inhibition of PDE-5 results in the accumulation of
cGMP, which exerts downstream effects on signaling cascades
associated with cardioprotection including PKG, PKC, ERK,
and GSK-3b.99 These drugs have been shown to increase the
levels of nitric oxide (NO), a signaling molecule active within
the RISK cascade.100
The main drugs in this category are sildenafil, vardenafil,
tadalafil, and avanafil. Sildenafil was originally investigated
for use in angina but was licensed for use in erectile dysfunc-
tion subsequently, as a large number of trial participants
described this side effect. Additionally, sildenafil and tadalafil
have been licensed for use in the management of pulmonary
arterial hypertension following the publication of several trials
showing their beneficial effect on pulmonary vascular endothe-
lium.101 There is also evidence for its beneficial effect in con-
gestive cardiac failure, high-altitude pulmonary edema, and
high-altitude pulmonary hypertension.102 With regard to the
conditioning effects of sildenafil, there are several animal stud-
ies showing a beneficial effect on infarct size. However, there
are no clinical trials in humans to date examining the role of
PDE-5 inhibitors in the context of ischemia/reperfusion.
Glyceryl Trinitrate or Nitroglycerin
Glyceryl trinitrate (GTN) is a nitrate that has been used for over
100 years in the treatment of unresponsive CHF, acute MI, left-
sided heart failure, and angina pectoris. It is also licensed for
use in cardiac surgery as an infusion. It is used as an agent to
lower and control the blood pressure and is also thought to
cause coronary vasodilation, thus maintaining graft patency
postoperatively.103 GTN functions as a NO donor that has sev-
eral effects on both the endothelium and the myocardium. The
NO within the endothelium inhibits platelet aggregation and
adhesion,104 smooth muscle cell migration,104 and adhesion
of inflammatory cells.105 In damaged or dysfunctional endothe-
lium, there is a reduction in NO, which could predispose graft
vessels to spasm and thrombosis. This in turn might result in
the development of accelerated atherosclerosis, resulting in
reduced patency.106 In the myocardium, NO plays an important
role in preventing reperfusion injury when the heart has been
preconditioned. It is an important part of the cascade of enzy-
matic reactions of the RISK pathway that is activated on reper-
fusion as a result of IPC,12 which in turn results in closure of the
MPTP. In animal models, it is has been well demonstrated that
NO donors infused into the heart,107 agents that increase myo-
cardial bioavailability of NO108 and increased intracellular NO
signaling within cardiomyocytes, may all be crucial to the pre-
conditioning effect.109 In this context, endogenous NO by itself
will not trigger conditioning and cardioprotection, but exogen-
ous NO serves as a trigger of preconditioning and is also an
important mediator of delayed preconditioning and
postconditioning.110
In the setting of AMI, there is evidence that intravenous
nitrates not only reduce infarct size but also result in a reduc-
tion in mortality. In a meta-analysis of 10 small trials, Yusuf
et al pooled the results of over 2000 patients that were
recruited. In all, 1021 patients received intravenous nitrates
with 136 deaths among them as opposed to 193 deaths among
1020 patients in the control group. The reduction in mortality
was significant.111 Conversely, the use of GTN as a condition-
ing agent is the setting of cardiac surgery has not been exam-
ined formally. In a 4-arm randomized controlled trial,
Kottenberg et al had randomized 176 nondiabetic patients
undergoing CABG to receive a sham or RIPC protocol under
isoflurane or propofol anesthesia.112 In a subsequent retrospec-
tive analysis of this study, patients in the control and RIPC
groups were analyzed with regard to the use of GTN. Using the
end point of troponin I AUC, there were no differences between
either of the groups. However, this study was specifically pow-
ered to pick up differences in the anesthetic regimes with and
without RIPC and not GTN.113 Overall, there is a case to be
made for the use of intravenous GTN in a large randomized
controlled trial examining its effects on myocardial ischemia/
reperfusion.
Atorvastatin
Atorvastatin is a cholesterol-lowering drug that has been shown
to have a range of pleiotropic effects. With regard to ischemia/
reperfusion, our group and others have shown that statins
reduce infarct size in animal models.114,115 This protection is
mediated via the RISK pathway including enzymes such as
PKC, ERK, Akt, and eNOS, independent of its cholesterol
lowering properties.114,116
Translation in clinical studies has been promising. The Ator-
vastatin for Reduction of Myocardial Damage During Angio-
plasty (ARMYDA) group of investigators, in the form of
several trials such as ARMYDA, ARMYDA-ACS, and ARMY
DA-RECAPTURE, have consistently shown that atorvastatin
therapy prior to elective or scheduled PCI reduces periproce-
dural myocardial injury as determined by troponin I release.
In fact, the ARMYDA-ACS and ARMYDA-RECAPTURE
studies showed a significant reduction in the major adverse car-
diovascular events such as death, MI, and revascularization
rates.117 In the STATIN STEMI trial, Kim et al randomized
patients with STEMI to 10 mg atorvastatin or 80 mg atorvasta-
tin prior to PCI and monitored for major adverse cardiovascular
events for 30 days after the procedure. There were no differ-
ences in events between either arms, but the high-dose arm had
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better myocardial flow postprocedure.118 In contrast, in the set-
ting of elective CABG surgery, our group randomized 58
patients to high-dose (160 mg) atorvastatin therapy given
acutely, in addition to their chronic therapy, 12 hours before
surgery. They performed a similar randomization in 52 patients
but instead gave the atorvastatin 2 hours before surgery. Both
the protocols resulted in no further protection as determined
by troponin I AUC.119 However, the final analysis after drop-
outs included only 45 and 51 patients, respectively, and the
studies may have been underpowered to detect any differences.
In summary, although there is evidence that chronic atorvasta-
tin therapy prior to PCI in elective or scheduled situations may
be beneficial, there is little evidence to support the use of acute
high-dose atorvastatin in either elective or emergency situa-
tions. Currently, there are no large randomized trials using
acute high-dose atorvastatin therapy.
Delcasertib
Delcasertib is a PKC-d antagonist that was developed by
Mochly-Rosen’s group. Although there are several isoforms
of PKC, the PKC-d isoform was discovered to be proapoptoic.
A selective PKC-d antagonist administered to adult cardiomyo-
cytes, Langendorff-perfused hearts, and in an in vivo mouse
model caused a reduction in injury following the index ische-
mia, while transgenic mice with the PKC-d-docking protein
upregulated (hence causing increased PKC-d activity) showed
increased damage following ischemia.120 Evidently, it also
improved recovery of function in human atrial muscle ex vivo
following simulated ischemia–reperfusion injury.121
This was first tested in man by the DELTAMI investigators,
when intracoronary delcasertib was administered in a phase II
trial at the time of PCI for acute STEMI.122 Although it had an
acceptable safety and tolerability profile, subsequent phase 3
trials failed to show adequate infarct size reductions, and
the drug was shelved by the sponsoring pharmaceutical
company.123
Nicorandil
Nicorandil is a derivative of nicontinamide that is coupled to
a NO donor. It acts as an opener of ATP-sensitive potassium
channels (K-ATP) and also provides a source of NO.124
Although external sources of NO have been shown to exert a
conditioning effect as discussed previously, opening of the
mitochondrial K-ATP (mito-K-ATP) channel is thought to
have a role as a mediator of preconditioning. For instance, diaz-
oxide, a K-ATP channel opener, administered to animal hearts
exert a similar infarct size reduction as IPC. Combining it with
5-hydroxydecanoate (5-HD), a blocker of the K-ATP channel,
abolishes it. Additionally, 5-HD also blocked IPC when admi-
nistered early but failed to do so when administered late, that is,
immediately prior to lethal ischemia.125 Nicorandil similarly
reduced infarct size to the same extent as IPC, and its effects
were partially abolished by 5-HD.126
The clinical trials testing nicorandil are far from conclusive.
The largest trial to date is the J-WIND trial that had a nicorandil
arm. A total of 613 patients were randomized to receive intra-
venous nicorandil as a bolus followed by an infusion or placebo
after primary PCI for acute STEMI. The total CK release was
not different in either group, and the overall morbidity and
mortality were the same in both the groups after 3 years. How-
ever, 61 patients were continued on oral nicorandil after dis-
charge, and in this group, the LV ejection fraction was better
at 6-month follow-up.57 On the other hand, in a randomized
trial involving 368 patients, intravenous nicorandil was given
before reperfusion therapy for STEMI, at a higher dose than
that in the J-WIND trial. This difference in timing and dosage
resulted in a significant reduction in cardiovascular death and
readmission to hospital for heart failure after a mean follow-
up period of 2.4 years.127 In the setting of CABG surgery, there
is 1 small proof of concept trial involving 32 patients, where
intravenous nicorandil infusion started prior to bypass and
continued for 2 hours after weaning off bypass could be cardi-
oprotective.128 There are currently no large trials underway to
examine the effects of nicorandil, but it is certainly worth
investigating.
Pharmacological Agents Acting on
the Mitochondria
Ciclosporin
Ciclosporin, an immunosuppressant drug, is a calcineurin inhi-
bitor that also prevents the formation of the MPTP by binding
with cyclophilin D (Cyp D), an important component of the
pore. This interaction with Cyp D prevents it from participating
in the formation of the pore and thus protects mitochondrial
integrity.129 The subsequent release of apoptotic factors is pre-
vented and cell death is avoided. Ciclosporin also protects
against myocardial ischemia/reperfusion injury.130 Although
the early studies administered ciclosporin during ischemia or
prior to reperfusion, subsequent evidence showed that ciclos-
porin administered at reperfusion could also protect the heart
and that this protection was linked to the MPTP.131,132 These
studies also showed that the effect of ciclosporin was related
to its Cyp D blockade rather than the ability to inhibit
calcineurin.
In a small proof of concept trial by Ovize’e group, 58
patients admitted with an acute STEMI were randomized to
receive either 2.5mg/kg of ciclosporin or placebo as a bolus
immediately after angiography but prior to PCI. Infarct size
was determined using troponin I AUC, which was significantly
smaller in the group that received ciclosporin. In this study, the
area at risk was determined by estimating the number of abnor-
mally contracting segments at coronary angiography. A regres-
sion analysis for area at risk against infarct size seemed to
indicate that the greater the area at the risk the larger the reduc-
tion in infarct size with ciclosporin. In other words, those that
had the largest area at risk benefitted most from ciclosporin. An
MRI scan at 5 days in subgroup of 28 patients confirmed
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Table 1. Pharmacological Agents That Have Been Tested in Clinical Trial, Which Simulate Myocardial Conditioning.
Mechanism of Action Clinical Trial N Number and Clinical Setting Result
Adenosine Adenosine receptors on
cell surface—likely A1
subtype but some
evidence for all
subtypes
AMISTAD 236 patients with STEMI treated
with thrombolysis
33% relative reduction in infarct size
Evidence of larger effect with
anterior STEMI
AMISTAD-II 2118 patients with anterior
STEMI treated with
thrombolysis or PCI
Reduced infarct size with 70 mg/kg/min
of adenosine—no reduction in
survival or rehospitalization with
CHF
AMP579 Adenosine A1 and A2
receptor antagonist
ADMIRE 311 patients undergoing PCI for
STEMI
No reduction in infarct size. Trend to
reduction in anterior STEMI
Bradykinin B2 receptor on cell
surface
Wang et al 41 patient undergoing CABG Reduction in CK-MB but no reduction
in troponin I
Remifentanil Opioid acting on m-
receptor on cell surface
Wong et al 40 patients undergoing CABG
surgery
Reduced CK-MB at 24 hours and
reduced troponin I at 12 hours
reduces arrhythmias postoperatively
and reduced time to extubation
Exenatide GLP-1 analogue acting via
cell surface receptors
Lonborg et al 172 patient with STEMI treated
with primary PCI
CMR 90 days later showed improved
myocardial salvage
Atrial natriuretic
peptide
Guanylyl cyclase receptors
that activates PKG and
prevents MPTP opening
J-WIND 569 patients with anterior STEMI
who had PCI or thrombolysis
Reduced CK-MB AUC after 72 hours,
reduced rehospitalization and death,
better ejection fraction at 6 months
Erythropoietin EPO-R receptor on cell
surface, which activates
RISK pathway, JAK-
STAT, and prevents
formation of the MPTP
Ludman et al 51 patients admitted with STEMI
treated with PCI given S/C
EPO 50 000 IU
No improvement in outcome with
increased incidence of MVO and LV
dilation.
REVEAL 222 patients with STEMI treated
with PCI and S/C EPO 60 000
IU within 4 hours of
reperfusion
No reduction in infarct size and a higher
rate of adverse cardiovascular
outcomes
Ferrario et al 30 patients with STEMI treated
with PCI given IV EPO 33 000
IU immediately prior with 2
further boluses at 24 and 48
hours
Reduction in CK-MB release and shift in
gene expression to antiapoptotic
spectrum
Prunier et al 110 patients with STEMI treated
with PCI given 1000 IU/kg of IV
EPO immediately after
reperfusion
Reduction in MVOwith improvement in
LV volume and function
Insulin Insulin cell surface
receptor activating
RISK pathway and
preventing opening of
MPTP
CREATE-ECLA 20 201 patients presenting with
STEMI treated with
thrombolysis or PCI
No morbidity or mortality benefit
Volatile anesthetics Activation of the RISK
pathway prevention of
MPTP opening
Penta de Peppo
et al
22 patients undergoing CABG
surgery treated with enflurane
Improved LV contractility
postoperatively
Belhomme et al 20 patients undergoing CABG
surgery treated with isoflurane
Reduced CK-MB and troponin I AUC
Nitrates Exogenous supply of nitric
oxide, which is a
signaling molecule in
RISK pathway
Yusuf et al Meta-analysis of 2000 patients in
10 trials with AMI receiving
nitrates
Reduction in infarct size and mortality
Kleibongard
et al
Retrospective analysis of 176
patients having elective CABG
No reduction in myocardial injury
Atorvastatin Pleiotropic effects of
activating eNOS/Akt-
ERK/PKC
ARMYDA,
ARMYDA-
ACS, and
ARMYDA-
RECAPTURE
Patients having elective or
scheduled PCI for angina/
NSTEMI
Reduction in troponin I release.
Reduction in MI, revascularization
rates, and death
STATIN STEMI 171 patients randomized to 10 or
80 mg atorvastatin prior to
PCI for STEMI
No difference in major cardiovascular
events but better myocardial blood
flow in high-dose group
Ludman et al 110 patients given 160 mg
atorvastatin prior to elective
CABG either 2 hours before
or 12 hours before
No difference in myocardial injury
(continued)
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a significant reduction in infarct size.133 These 28 patients went
on to have an MRI scan at 6 months, which confirmed the
persistence of the infarct size reduction with a significantly
lower LV end systolic volume in patients who received ciclos-
porin.134 Currently, the same group is now recruiting for a large
multicenter randomized controlled trial (CIRCUS) involving
1000 patients, examining the effects of ciclosporin.
The Future of Pharmacological Conditioning
Since the first description of IPC in 1986, several trials have
been conducted using pharmacological agents to reduce ische-
mia/reperfusion injury. Although the animal evidence for many
agents has been robust, translation in humans has not materia-
lized. Part of the reason why could be the complexity of human
patients with their multiple comorbidities and polypharmacy.
These patients could be taking a number of pharmacological
agents that might block protection or conversely have already
activated cardioprotective pathways. For example, recent animal
evidence has implicated that platelet inhibitors, such as abcixi-
mab, clopidogrel, and cangrelor, commonly used after AMI and
prior to PCI, may reduce reperfusion injury and infarct size by
postconditioning the heart.135-137 Another factor could be the
advances made in the fields of interventional cardiology, cardiac
surgery, cardiac anesthesia, and critical care, which have mini-
mized the procedural risks, optimized techniques, and fine-
tuned pre- and post-procedural care. Or perhaps the dosage, tim-
ing, rate, and route of administration of these agents have to be
perfectly balanced, which could involve going back to the ani-
mal laboratory to conduct yet more scientific experiments.
Nonetheless, some agents show more promise than others,
including exenatide, PDE-5 inhibitors, nitrates, and ciclosporin
(Table 1). The results of a few multicenter randomized trials are
awaited, whereas some are yet to be undertaken. In 2008, cardi-
ovascular diseases accounted for 48% of all deaths due to non-
communicable diseases.1 Pharmacological conditioning can be
used as part of a multifaceted approach to improving clinical
outcomes in patients who have ischemic heart disease.
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